Page 4 - Activity Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

For well under $100, Amazon's Halo View health tracker is an excellent tool to help-kick start your fitness journey.

All Specs Lots of fitness trackers can measure your calories burned, heart rate, and steps. With the Halo, Amazon wants to give you greater visibility into your overall health, along with actionable insights to help improve it. Priced at $99.99 for the band plus $3.99 per month for a membership (after a six-month free trial), the Halo does an excellent job of monitoring your activity and sleep, and its companion app gives you access to a wide range of workouts and wellness programs. In addition, the Halo has the ability to analyze the tone of your voice to tell you how you sound to other peo...

Okay, first impressions: The ring takes a few minutes to set up. Once you pair it to your smart device via the free Oura app , you're prompted to answer a few questions, such as your height, weight, and current goals. I chose the somewhat broad "Improve my health," but other options include "Be productive and energetic" and "Manage stress levels." From there, you slip the ring onto your finger — any digit is doable, though index, middle, or ring tend to work best, according to the brand — and it will start reading your heart rate and body temperature. By the next day, you'll start recei...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 ... ChemoCentryx, Inc.December 21, 2020 GMT As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the...

Share: As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo Avacopan safe and well tolerated in C3G patients ChemoCentryx and VFMCRP plan to discuss registr...